William Blair & Company’s Corcept Therapeutics CORT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $750K | Buy |
8,627
+2,260
| +35% | +$136K | ﹤0.01% | 1078 |
|
|
2026
Q1 | $257K | Buy |
6,367
+75
| +1% | +$2.8K | ﹤0.01% | 1390 |
|
|
2025
Q4 | $219K | Buy |
6,292
+1,020
| +19% | +$80.1K | ﹤0.01% | 1429 |
|
|
2025
Q3 | $438K | Sell |
5,272
-33
| -0.6% | -$2.39K | ﹤0.01% | 1160 |
|
|
2025
Q2 | $389K | Buy |
5,305
+55
| +1% | +$3.99K | ﹤0.01% | 1164 |
|
|
2025
Q1 | $600K | Hold |
5,250
| – | – | ﹤0.01% | 1035 |
|
|
2024
Q4 | $265K | Hold |
5,250
| – | – | ﹤0.01% | 1332 |
|
|
2024
Q3 | $243K | Buy |
+5,250
| New | +$187K | ﹤0.01% | 1373 |
|
|
2020
Q2 | – | Sell |
-23,206
| Closed | -$276K | – | 1684 |
|
|
2020
Q1 | $276K | Hold |
23,206
| – | – | ﹤0.01% | 1043 |
|
|
2019
Q4 | $281K | Sell |
23,206
-739
| -3% | -$10.3K | ﹤0.01% | 1194 |
|
|
2019
Q3 | $338K | Sell |
23,945
-2,060
| -8% | -$25.3K | ﹤0.01% | 1077 |
|
|
2019
Q2 | $290K | Sell |
26,005
-995
| -4% | -$11.1K | ﹤0.01% | 1158 |
|
|
2019
Q1 | $317K | Hold |
27,000
| – | – | ﹤0.01% | 1128 |
|
|
2018
Q4 | $361K | Hold |
27,000
| – | – | ﹤0.01% | 1026 |
|
|
2018
Q3 | $379K | Hold |
27,000
| – | – | ﹤0.01% | 1045 |
|
|
2018
Q2 | $424K | Hold |
27,000
| – | – | ﹤0.01% | 999 |
|
|
2018
Q1 | $444K | Hold |
27,000
| – | – | ﹤0.01% | 957 |
|
|
2017
Q4 | $488K | Hold |
27,000
| – | – | ﹤0.01% | 973 |
|
|
2017
Q3 | $521K | Hold |
27,000
| – | – | ﹤0.01% | 920 |
|
|
2017
Q2 | $319K | Hold |
27,000
| – | – | ﹤0.01% | 1158 |
|
|
2017
Q1 | $243K | Hold |
27,000
| – | – | ﹤0.01% | 1152 |
|
|
2016
Q4 | $196K | Hold |
27,000
| – | – | ﹤0.01% | 1160 |
|
|
2016
Q3 | $176K | Buy |
+27,000
| New | +$157K | ﹤0.01% | 1186 |
|
|
2016
Q2 | – | Sell |
-27,000
| Closed | -$126K | – | 1236 |
|
|
2016
Q1 | $126K | Hold |
27,000
| – | – | ﹤0.01% | 1113 |
|
|
2015
Q4 | $134K | Hold |
27,000
| – | – | ﹤0.01% | 1131 |
|
|
2015
Q3 | $101K | Hold |
27,000
| – | – | ﹤0.01% | 1339 |
|
|
2015
Q2 | $162K | Buy |
27,000
+7,000
| +35% | +$42.9K | ﹤0.01% | 2083 |
|
|
2015
Q1 | $112K | Hold |
20,000
| – | – | ﹤0.01% | 2055 |
|
|
2014
Q4 | $60K | Hold |
20,000
| – | – | ﹤0.01% | 2042 |
|
|
2014
Q3 | $53K | Buy |
20,000
+10,000
| +100% | +$26.5K | ﹤0.01% | 2049 |
|
|
2014
Q2 | $28K | Buy |
+10,000
| New | +$29.5K | ﹤0.01% | 2049 |
|
Other funds holding CORT
ISL
PA
William Blair & Company's CORT Position: Q2 2026 in Review
William Blair & Company increased its Corcept Therapeutics (CORT) stake by 35% in Q2 2026, buying an estimated $136K and bringing the position to 8,627 shares worth $750K. The position accounts for ﹤0.01% of the portfolio, ranked #1078.
William Blair & Company first reported a position in CORT in Q2 2014 and has held it in 31 quarters since. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.
- William Blair & Company held 8,627 shares of Corcept Therapeutics worth $750K as of Q2 2026.
- William Blair & Company bought 2,260 Corcept Therapeutics shares in Q2 2026, an estimated $136K.
- Corcept Therapeutics made up ﹤0.01% of William Blair & Company's portfolio in Q2 2026, its #1078 holding.
- William Blair & Company first reported a position in Corcept Therapeutics in Q2 2014 and has held it in 31 quarters since.
- 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.
Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.